专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013164788A2 METHOD 审中-公开
标题翻译：方法
公开(公告)号：WO2013164788A2
公开(公告)日：2013-11-07
申请号：PCT/IB2013/053488
申请日：2013-05-02
申请人： BERGENBIO AS
发明人： LORENS, Jim , TIRON, Crina
IPC分类号： G01N33/50 , G01N33/574
CPC分类号： G01N33/573 , A61K38/45 , A61K45/06 , C12Y207/11 , G01N33/502 , G01N33/5073 , G01N33/574 , G01N33/57496 , G01N2333/91205 , G01N2800/50
摘要： The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to- mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
摘要翻译：在本文中公开了使用Akt3作为检测受试者中上皮 - 间质转化（EMT）的发生的生物标志物，以及使用Akt3抑制剂治疗癌症。还公开了通过测量Akt3表达和/或活性来检测受试者中上皮 - 间质转换（EMT）的发生的各种方法。

2. 发明申请

WO2007089367A2 METHODS OF USING HEDGEHOG KINASE ANTAGONISTS TO INHIBIT HEDGEHOG SIGNALING AND TO TREAT HEDGEHOG MEDIATED DISORDERS 审中-公开
标题翻译：使用HEDGEHOG激酶拮抗剂抑制HEDGEHOG信号并治疗HEDGEHOG介导的疾病的方法
公开(公告)号：WO2007089367A2
公开(公告)日：2007-08-09
申请号：PCT/US2006/062052
申请日：2006-12-13
申请人： GENENTECH, INC. , CURIS, INC. , DE SAUVAGE, Frederic, J. , EVANGELISTA, Marie
发明人： DE SAUVAGE, Frederic, J. , EVANGELISTA, Marie
IPC分类号： C12N15/113
CPC分类号： C12Q1/485 , A61K31/7088 , A61K38/45 , A61K47/54 , A61K47/56 , A61K47/62 , A61K47/6803 , A61K47/6809 , A61K47/6811 , A61K47/6843 , A61K48/00 , C07K16/40 , C12N15/1137 , C12N2310/14 , C12N2310/351 , C12Y207/11 , C12Y207/12001 , G01N33/5011 , G01N33/5058 , G01N33/574 , G01N33/6893 , G01N2800/10 , G01N2800/12 , G01N2800/20 , G01N2800/28 , A61K2300/00
摘要： The present invention provides for a method of using CDC2L1, CSNK1A1, GYK, NEK1, PLK1, PRKAR1A, PRKRA, TTBK2 or TTK hedgehog kinase antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.
摘要翻译：本发明提供了使用CDC2L1，CSNK1A1，GYK，NEK1，PLK1，PRKAR1A，PRKRA，TTBK2或TTK hedgehog激酶拮抗剂抑制刺猬蛋白信号传导的方法，以及治疗和诊断与刺猬蛋白信号传导或刺猬过度表达相关的疾病，包括癌症，细胞增殖性疾病和血管发生，神经障碍，以及受刺猬蛋白信号传导如毛发生长，神经干细胞分化，软骨形成和成骨，肺表面活性物质生成，肺细胞中层状体形成的其他病症。

3. 发明申请

WO2016193959A2 IMPROVED PRODUCTIVITY AND BIOPRODUCT FORMATION IN PHOTOTROPIN KNOCK/OUT MUTANTS IN MICROALGAE 审中-公开
标题翻译：在微藻中改善光合作用的生物量和生物量
公开(公告)号：WO2016193959A2
公开(公告)日：2016-12-08
申请号：PCT/IB2016/054466
申请日：2016-07-26
申请人： NMC, INC. , LOS ALAMOS NATIONAL SECURITY, LLC
发明人： NEGI, Sangeeta , SAYRE, Richard Thomas , STARKENBURG, Shawn Robert
IPC分类号： C12P19/04 , C12N1/13
CPC分类号： C12N9/12 , C07K14/405 , C12N1/12 , C12N9/0051 , C12N9/1205 , C12N9/22 , C12N15/01 , C12N15/11 , C12N2310/20 , C12N2800/80 , C12P7/64 , C12P19/04 , C12P23/00 , C12Y108/01009 , C12Y207/11
摘要： Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii , phototropin plays a vital role in progression of the sexual life cycle and In the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 μmol photons m -2 s -1 ). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes. With respect to photosynthetic electron transport genes, genes encoding proteins of the cytochrome b6f and ATP synthase complex were up regulated potentially facilitating proton-coupled electron transfer. In addition genes involved in limiting steps in the Calvin cycle Ribulose-1,5-blsphosphate carboxylase/oxygenase (RuBisCO), Sidoheptulose 1,7 bisphosphatase (SBPase), Glyceraldehyde-3- phosphate dehydrogenase (3PGDH) and that mediate cell-cycle control (CDK) were also up regulated along with starch synthase and fatty acid biosynthesis genes involved in starch and lipid synthesis, in addition, transmission electron micrographs show increased accumulation of starch granules in PHOT mutant compared to wild type, which is consistent with the higher expression of starch synthase genes. Collectively, the altered patterns of gene expression in the PHOT mutants were associated with a two-fold increase in growth and biomass accumulation compared to wild type when grown in environmental photobioreactors (Phenometrics) that simulate a pond environment. In conclusion, our studies suggest that phototropin may be a master gene regulator that suppresses rapid cell growth and promotes gametogenesis and sexual recombination in wild type strains.
摘要翻译：光吗啉是蓝光受体，其介导植物和藻类中各种蓝光引发的生理过程。在高等植物中，这些过程包括光转动，叶绿体运动和气孔开放。在绿藻藻衣藻中，光滑石在性生活周期的进展中起着至关重要的作用，并且在眼睛斑点大小和光敏感性的控制中。光喜素也参与蓝光介导的叶绿素，类胡萝卜素，叶绿素合成的变化结合蛋白。我们比较了光诱导敲除（PHOT KO）突变体和野生型亲本的转录组，以分析高光生长培养物（500μmol光子m-2s-1）中基因表达的差异。我们的结果表明参与光合电子传递链，碳固定途径，淀粉，脂质和细胞周期控制基因的基因的上调。对于光合电子转运基因，编码细胞色素b6f和ATP合成酶复合物蛋白质的基因上调可能促进质子 - 偶联电子转移。此外，参与限制加尔文周期中的步骤的基因Ribulose-1,5-blsphosphate羧化酶/加氧酶（RuBisCO），Sidoheptulose 1,7二磷酸酶（SBPase），甘油醛-3-磷酸脱氢酶（3PGDH），并介导细胞周期控制（CDK）也与淀粉合成酶和脂肪酸生物合成基因参与淀粉和脂质合成相关，此外，透射电子显微照片显示，与野生型相比，透明电子显微照片显示淀粉颗粒在PHOT突变体中的积累增加，这与更高的表达一致的淀粉合成酶基因。总之，在模拟池塘环境的环境光生物反应器（Phenometrics）中生长时，与野生型相比，PHOT突变体中基因表达的改变模式与生长和生物量积累相比增加了两倍。总之，我们的研究表明光滑素可能是一个主要的基因调节器，抑制快速的细胞生长和促进野生型菌株的配子形成和性重组。

4. 发明申请

WO2013164788A3 METHOD 审中-公开
标题翻译：方法
公开(公告)号：WO2013164788A3
公开(公告)日：2014-01-23
申请号：PCT/IB2013053488
申请日：2013-05-02
申请人： BERGENBIO AS
发明人： LORENS JIM , TIRON CRINA
IPC分类号： G01N33/50 , G01N33/574
CPC分类号： G01N33/573 , A61K38/45 , A61K45/06 , C12Y207/11 , G01N33/502 , G01N33/5073 , G01N33/574 , G01N33/57496 , G01N2333/91205 , G01N2800/50
摘要： The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to- mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
摘要翻译：在本文中公开了使用Akt3作为检测受试者中上皮 - 间质转化（EMT）的发生的生物标志物，以及使用Akt3抑制剂治疗癌症。还公开了通过测量Akt3表达和/或活性来检测受试者中上皮 - 间质转换（EMT）的发生的各种方法。

5. 发明申请

WO2013134766A2 IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS 审中-公开
标题翻译：分子生物学途径的鉴定及其使用方法，用于治疗神经损伤和其他神经损伤性疾病
公开(公告)号：WO2013134766A2
公开(公告)日：2013-09-12
申请号：PCT/US2013/030203
申请日：2013-03-11
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： ZACK, Donald J. , WELSBIE, Derek S.
IPC分类号： A61K48/00 , A61P25/28 , A61P25/00
CPC分类号： C12N15/1137 , A61K31/553 , A61K31/713 , C12N2310/14 , C12N2320/30 , C12Q1/485 , C12Q1/6883 , C12Q2600/136 , C12Y207/10 , C12Y207/11 , C12Y207/99 , G01N2500/04

6. 发明申请

WO2012012467A2 MODULATION OF NUCLEAR-RETAINED RNA 审中-公开
标题翻译：核保留RNA的调节
公开(公告)号：WO2012012467A2
公开(公告)日：2012-01-26
申请号：PCT/US2011/044583
申请日：2011-07-19
申请人： ISIS PHARMACEUTICALS, INC. , BENNETT, C., Frank
发明人： BENNETT, C., Frank
IPC分类号： A61K48/00
CPC分类号： C12N15/1137 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525 , C12Y207/11 , C12N2310/322 , C12N2310/3533 , C12N2310/3527
摘要： Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.
摘要翻译：本文提供了用于降低动物中nrRNA表达的方法，化合物和组合物。本文还提供用于治疗，改善，延缓或减轻与动物中的核保留RNA相关的疾病或病症的症状的方法，化合物和组合物。此类方法，化合物和组合物可用于治疗，预防，延缓或改善与核保留RNA或其症状相关的疾病或病症。

7. 发明申请

WO2015155738A3 USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY 审中-公开
标题翻译：使用GSK-3抑制剂或激活剂，其调节PD-1或T-BET表达以调节T细胞免疫
公开(公告)号：WO2015155738A3
公开(公告)日：2016-01-07
申请号：PCT/IB2015052606
申请日：2015-04-09
申请人： RUDD CHRISTOPHER
发明人： RUDD CHRISTOPHER , LEE DAE CHOON , ROTHSTEIN DAVID MARK , LEE YOUNG MEE
IPC分类号： A61K38/45 , A61K31/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P37/00 , G01N33/50
CPC分类号： A61K31/404 , A61K9/0053 , A61K31/4015 , A61K31/4035 , A61K31/426 , A61K31/433 , A61K31/506 , A61K38/10 , A61K38/45 , A61K45/06 , A61K2039/505 , C07K16/2818 , C12Y207/11 , G01N33/5008 , A61K2300/00
摘要： The present application generally relates to the discovery that glycogen synthase kinase 3 (GSK-3) is an upstream signalling molecule that controls PD-1 transcription and Tbet expression by immune cells and in particular T-cells. Based on this discovery, and in view of the known immunosuppressive effect of PD-1 on immunity and the promoting effect of Tbet on T cell immunity, the present invention relates to the use of GSK-3 inhibitors to promote immunity, including cytotoxic T cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting PD-1 expression and/or blockade or Tbet upregulation is therapeutically desirable such as cancer and infectious conditions. Further, based on this discovery the present invention relates to the use of compounds which promote GSK-3 expression or activity to suppress immunity, especially aberrant T cell immunity in subjects in need thereof, e.g., subjects with chronic conditions wherein PD-1 upregulation or Tbet down regulation is therapeutically desirable such as allergic, autoimmune or inflammatory conditions. Also, screening methods for identifying immune agonists and antagonists, especially antibodies, are provided.
摘要翻译：本申请通常涉及糖原合酶激酶3（GSK-3）是控制免疫细胞特别是T细胞的PD-1转录和Tbet表达的上游信号分子的发现。基于这一发现，鉴于PD-1对免疫力的已知免疫抑制作用和Tbet对T细胞免疫的促进作用，本发明涉及GSK-3抑制剂在促进免疫中的应用，包括细胞毒性T细胞特别是抑制PD-1表达和/或阻断或Tbet上调的慢性病症的受试者在治疗上是有希望的，例如癌症和感染性疾病。此外，基于这一发现，本发明涉及促进GSK-3表达或活性以抑制免疫的化合物的用途，特别是有需要的受试者中的异常T细胞免疫，例如具有慢性疾病的受试者，其中PD-1上调或 Tbet down调节是治疗上需要的，例如过敏，自身免疫或炎性病症。此外，提供用于鉴定免疫激动剂和拮抗剂，特别是抗体的筛选方法。

8. 发明申请

WO2015048331A1 COMPOUNDS FOR INDUCING ANTI-TUMOR IMMUNITY AND METHODS THEREOF 审中-公开
标题翻译：用于诱导抗肿瘤免疫的化合物及其方法
公开(公告)号：WO2015048331A1
公开(公告)日：2015-04-02
申请号：PCT/US2014/057525
申请日：2014-09-25
申请人： CORNELL UNIVERSITY
发明人： CUBILLOS-RUIZ, Juan, R. , GLIMCHER, Laurie, H.
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , A61K45/06 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2320/31 , C12Y207/11
摘要： Described herein is a previously unknown function of XBPl in controlling anti-tumor immunity. It is shown that inhibiting XBPl in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
摘要翻译：本文描述了XBP1在控制抗肿瘤免疫中的以前未知的功能。显示抑制肿瘤相关树突细胞中的XBP1抑制肿瘤生长并诱导保护性抗肿瘤免疫应答。

9. 发明申请

WO2013091293A1 人NLK基因相关的用途及其相关药物审中-公开
公开(公告)号：WO2013091293A1
公开(公告)日：2013-06-27
申请号：PCT/CN2012/070537
申请日：2012-01-18
申请人：上海吉凯基因化学技术有限公司 , 韩海雄 , 朱向莹 , 孙琴 , 顾雪峰 , 谢胜华 , 李杨 , 金杨晟 , 瞿红花 , 曹跃琼
发明人：韩海雄 , 朱向莹 , 孙琴 , 顾雪峰 , 谢胜华 , 李杨 , 金杨晟 , 瞿红花 , 曹跃琼
IPC分类号： A61K48/00 , C12N15/113 , C12N15/867 , C12N15/11 , A61P35/00
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/531 , C12N2799/027 , C12Y207/11
摘要：提供了NLK基因的用途及其相关药物。还提供了NLK基因在肿瘤治疗、肿瘤诊断及药物制备中的用途。进一步构建了可降低肿瘤细胞中NLK基因表达的分离的分子、含有该分离的分子的细胞及NLK基因干扰慢病毒。可降低肿瘤细胞中NLK基因表达的分离的分子或者NLK基因干扰慢病毒能够特异性抑制人NLK基因的表达，尤其是慢病毒，能够高效侵染靶细胞，高效率地抑制靶细胞中NLK基因的表达，进而抑制肿瘤细胞的生长，促进肿瘤细胞凋亡，能够用于肿瘤治疗。

10. 发明申请

WO2009065080A1 COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS 审中-公开
标题翻译：用于在循环系统细胞中操作PIM-1活性的组合物和方法
公开(公告)号：WO2009065080A1
公开(公告)日：2009-05-22
申请号：PCT/US2008/083693
申请日：2008-11-14
申请人： SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION , MURASKI, John, A., Jr. , SUSSMAN, Mark, A.
发明人： MURASKI, John, A., Jr. , SUSSMAN, Mark, A.
IPC分类号： C12N5/08
CPC分类号： A61K38/45 , A61K35/28 , A61K2035/124 , C12N9/12 , C12N15/86 , C12Y207/11 , C12Y207/12 , A61K2300/00
摘要： The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-I, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-I, and methods for enhancing the regenerative potential of stem cells in the heart.
摘要翻译：本发明提供包含编码丝氨酸/苏氨酸激酶PIM-1的核酸的组合物（例如，药物组合物），以及制备和使用它们的方法; 包括诱导细胞增殖的方法，以及保护心脏细胞免受缺氧和细胞凋亡的影响。本发明提供了包含编码PIM-1的核酸的组合物（例如，药物组合物），以及用于增强心脏中干细胞再生潜能的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式